Healthcare Public-Private Partnership

Transcription

1 WHY YOU CANNOT MISS OUT ON THIS EVENT Private healthcare expenditure, whose beneficiaries are the more affluent members of societies, is higher than public healthcare expenditure, which is being relied upon by the mass population. Infectious diseases are emerging and non-communicable diseases within ageing population are rising in the region. Due to budget constraints and quality issues, governments are finding it difficult to find ways of solving these health challenges. The Public-Private Partnership (PPP) model can help address the challenges of an ageing healthcare system nationally where the patient quality care and ability to provide affordable service to the masses are at a breaking point. It can help improve public health results, while meeting the objectives of each of the partners. However, the PPP model cannot be seen as a be-all and end-all model without first understanding the complexities of undertaking partnerships with two very distinct entities: Governments and corporations. Trueventus Healthcare Public-Private Partnership conference aims to provide both sides of the partnership with the technical knowledge and resources to effect long-lasting and positive outcome for those who matter: The public. We have gathered together subject matter experts who will discuss and share their expertise in delivering successful and replicable PPP projects for the healthcare sector. KEY FEATURES OF THIS CONFERENCE: Differentiating PPP from traditional procurement Choosing the right Healthcare PPP model Discovering Healthcare PPP financing schemes Mitigating investment risks Managing a Healthcare PPP Project Recognising the benefits of employing PPP in health Reviewing lessons learned from past healthcare PPP projects Exploring potential Healthcare PPP projects FEATURING INTERNATIONAL PRESENTATIONS BY: Darrin Grimsey Partner, Infrastructure Advisory Ernst & Young, Australia Akmal Arief Chief Operating Officer National Heart Institute of Malaysia Dr Mary Moran Executive Director Policy Cures, Australia Etienne Szivo Head of Healthcare, ASEAN, South Korea and Pacific Siemens Pte Ltd, Singapore Andreas Roost General Manager Value Added Services Siemens Ltd, Australia Dr Jean-Paul Deslypere Chief Executive Officer Bioscience Training Institute Pte Ltd, Singapore Roger Thompson Director, Consulting Pricewaterhouse Coopers, Hong Kong Abigael Ati Monitoring and Evaluation Specialist High Five Program John Hopkins University Center for Communications Program, Indonesia Dr HM Goh Medical Director/Chief Operating Officer University of Malaya Specialist Centre FEATURING LOCAL PRESENTATIONS BY: Undersecretary Teodoro Herbosa Undersecretary of Health Department of Health, Philippines Romina Danguilan, MD Head, Hemodialysis Center National Kidney and Transplant Institute Joseph Lufkin Founder/Director IFCL Group Atty. Luther Ramos Partner Puyat Jacinto & Santos Law Eduardo Francisco President BDO Capital & Investment Corporation Dr Elmer Soriano Country Director Access Health International, Philippines PG.1

2 CONFERENCE AT A GLANCE Day 1: Wednesday, June 19, 2013 Session One Overview of Healthcare PPP in Southeast Asia: Charting the next 10 years Session Two Healthcare PPP and hybrid healthcare model: Experience from a large teaching medical centre in Malaysia Session Three Improving service delivery through Healthcare Public-Private Partnership Session Four - Case Study National Kidney and Transplant Institute: Innovation without capital outlay Session Five Learning from past projects for a better delivery tomorrow: Service delivery models Session Six Transplanting overseas best practices into a local setting within the national context, needs and budget Session Seven Alternative funding models: Financing Healthcare PPPs Session Eight Gaining advantages by turning to Public-Private Partnerships in building the Cancer Center of the Philippines and modernising the Philippine Orthopedic Center Day 2: Thursday, June 20, 2013 Session One Healthcare PPP: Matching private donors with the funding needs of small local greenfield medical clinics s Chief Executive Officers Managing Directors Chief Investment Officers Chief Financial Officers Chief Operating Officers Vice Presidents Hospital Administrators Hospital Infrastructure, Facilities and Expansion Directors Healthcare Delivery Service Managers Project Directors/Managers Country Managers Heads of Project Financing Investors Secretaries/Ministers of Health Policy Makers Key Industries Federal, state and local government National, state, specialist, university and local hospitals Private health providers Medical equipment manufacturers and suppliers Pharmaceutical companies Construction companies Finance and insurance Session Two Healthcare PPP: Financing of vaccines, immunisation and research and development of new pharmaceuticals Session Three Health innovation fund: Accelerating PPP innovations through venture capital Session Four - Case Study The learning partnership: Increasing competencies through knowledge sharing Aman Tirta Session Five Synergy: Efficiency in service delivery through the sharing of strengths between private partner and the government Session Six Managing healthcare PPP risks efficiently Session Seven Continuity guarantee: Providing safeguards from policy and leadership changes Session Eight Securing the return on investment: Management of costs and payments PG.2

3 Day 1: Wednesday, June 19, Registration and coffee 1230 Networking Luncheon 0845 Opening address from the Chairperson 0900 Session One Overview of Healthcare PPP in Southeast Asia: Charting the next 10 years Alleviating resource and financial limitations in providing quality care to a growing/ageing ASEAN population Transforming healthcare services through PPP: Innovation, delivery speed and methods, efficiency and outreach Assessing opportunities and overcoming PPP constraints by geolocation Roger Thompson Director, Consulting Pricewaterhouse Coopers, Hong Kong 0945 Session Two Healthcare PPP and hybrid healthcare model: Experience from a large teaching medical centre in Malaysia University of Malaya (UM) leverage on PPP models in driving organisation transformation. PPP model plays a pivotal role in the strategy of managing the growth, human capital and financial sustainability. Critical success factor in maintaining a symbiotic relationship between a public teaching hospital and private hospital Aligning PPP strategy to support Care, Research, Education agenda in UM Health Metropolis Using PPP as a catalyst in driving institutional transformation, leadership reform and clinical governance Dr HM Goh Medical Director/Chief Operating Officer University of Malaya Specialist Centre 1400 Session Five Learning from past projects for a better delivery tomorrow: Service delivery models Overviewing the PPP model past, present and future The Australian market, lessons learned Looking to the future: A new paradigm for PPPs in health Considering future implications on funding and financing projects Darrin Grimsey Partner, Infrastructure Advisory Ernst & Young Australia 1445 Session Six Transplanting overseas best practices into a local setting within the national context, needs and budget Performance metrics: Discussing how Siemens is getting expertise in managed equipment service (MES) and PPPs Transferring the success of the Fiona Stanley Hospital project into a local context: Easier said than done Looking through the lens of a vendor: Risk vs benefits Etienne Szivo Head of Healthcare, ASEAN, South Korea and Pacific Siemens Pte Ltd, Singapore Andreas Roost Chief Operating Officer Siemens Ltd, Australia 1530 Afternoon Refreshments 1030 Morning Refreshments 1100 Session Three Improving service delivery through Healthcare Public- Private Partnership Ownership structure of the National Heart Institute of Malaysia Improving delivery and partner relationship: Operational guidance by the Ministry of Health Improvements in service delivery that were realised from using a PPP model Akmal Arief Chief Operating Officer National Heart Institute of Malaysia 1145 Session Four - Case Study National Kidney and Transplant Institute: Innovation without capital outlay Rationalising Public-Private Partnership for the Hemodialysis Centre Project - Operational concerns - Financial concerns Evaluating the dialysis centre financial performance Analysing the effect on the over-all financial performance of National Kidney Transplant Institute Renewal of the project after 5 years Romina Danguilan, MD Head, Hemodialysis Center National Kidney and Transplant Institute 1600 Session Seven Alternative funding models: Financing Healthcare PPPs Deep-diving and revisiting the role of private sector vs public sector in financing healthcare Funding instruments available to fund healthcare projects Challenges and ensuring projects are viable Eduardo Francisco President BDO Capital & Investment Corporation 1645 Session Eight Gaining advantages by turning to Public-Private Partnerships in building the Cancer Center of the Philippines and modernising the Philippine Orthopedic Center Discerning the financial viability of the projects through Public- Private Partnership Cross-implementing operational benefits that may be derived from the projects Delving into the project details and setting corrective measures for future/on-going projects Undersecretary Teodoro Herbosa Undersecretary of Health Department of Health, Philippines 1730 End of Day One PG.3

4 Day 2: Thursday, June 20, Registration and coffee 1230 Networking Luncheon 0845 Welcome address from the Chairperson 0900 Session One Healthcare PPP: Matching private donors with the funding needs of small local greenfield medical clinics Needs for small community healthcare (SCHC) micro-infrastructure in the Philippines What is a typical SCHC infra asset? Current goverment programmes to push SCHC infrastructure into the provinces Donor/development partner initiatives to date Critical role of private corporate philanthropy in building SCHC infrastructure Individual corporate CSR programmes vs collective efforts through multi-donor foundations Current mechanisms for CSR funding of SCHC projects What needs to be done? Joseph Lufkin Founder/Director IFCL Group 0945 Session Two Healthcare PPP: Financing of vaccines, immunisation and research and development of new pharmaceuticals Providing an alternative when the public purse cannot be stretched furthur: - The Asia-Pacific vaccine lag - Missing medicines Using private capital and consumer funds to supplement health budgets Weighing the success of Product Development Partnerships Dr Mary Moran Executive Director Policy Cures, Australia 1030 Morning Refreshments 1100 Session Three Health innovation fund: Accelerating PPP innovations through venture capital Understanding the roles of venture capital in promoting health PPP innovations Knowing the benefits and challenges from accelerating health PPP innovations through venture capital Overcoming challenges to realise the benefits of health PPP innovations through venture capital Dr Elmer Soriano Country Director Access Health International, Philippines 1145 Session Four - Case Study The learning partnership: Increasing competencies through knowledge sharing between partners - Aman Tirta Looking at the partnership in Aman Tirta: their expertise and what they brought into the table Engaging the other partners and getting them involved Determining the knowledge transfer: What was shared? How did we share? What we learned from and about the partnership What we learned from our partners: How far are we now from our last stance? Abigael Ati Monitoring and Evaluation Specialist High Five Program CCP Indonesia 1400 Session Five Synergy: Efficiency in service delivery through the sharing of strengths between private partner and the government Building a complementary relationship to alleviate inefficiencies in healthcare service delivery Filling-in service delivery gaps through PPP Advantages and benefits of the partnership as compared to having the services provided solely by the government Jean-Paul Deslypere Chief Executive Officer Bioscience Training Institute Pte Ltd 1445 Session Six Managing healthcare PPP risks efficiently Take a step back: Reviewing common and region-specific risks of the PPP lifecycle Structuring risk management programmes Constructing risk assessment and mitigation tools along the project value chain Putting in place alternative/contingency arrangements caused by undefined/unexpected changes Speaker to be advised 1530 Afternoon Refreshments 1600 Session Seven Continuity guarantee: Providing safeguards from policy and leadership changes Any consideration in selecting PPP as the preferred model should be designed around realpolitik in order for its effects to be trickled down to the citizens. Sustainable benefits and transparency of scope, scale and returns should be designed into the contract to counteract government and policy changes, which could derail the PPP investment. Selecting the right partners to lead the programme within the local and federal government structure Integrating safety mechanisms and communication channels: Transition period and after Roadmapping clear exit strategies and removing potential barriers Speaker to be advised 1645 Session Eight Securing the return on investment: Management of costs and payments Identifying the principals, arrangements and service level agreements (SLAs) Detailing the payment mechanism and risk allocation Reviewing additional adjustments Choosing the right benchmark: Similar projects or verticals Evaluating alternative payment structures Atty. Luther Ramos Partner Puyat Jacinto & Santos Law 1730 End of Conference PG.4

5 COMPANY DETAILS Name Address Postcode Industry Country Fax REGISTER NOW : Fax: : ryanw@trueventus.com ATTENDEE DETAILS 1 Name APPROVAL NB: Signatory must be authorised on behalf of contracting organisation. Name Authorising Signature 2 Name 3 Name 4 Name 5 Name COURSE FEES USD1595 per delegate Documentation Package USD 495 All options inclusive of delegate pack, luncheon and refreshments. Fax MN-PH08 TERMS & CONDITIONS 1. The course fee is inclusive of the event proceedings, materials, refreshment and lunch. 2. Upon receipt of the complete registration form, invoice will be issue. Trueventus request that all payments be made within 5 working days of the invoice being issued. Full payment must be received prior to the event. Only delegates that have made full payment will be admitted to event. 3. Substitution & cancellations policy. Should the registered delegate is unable to attend, a substitute delegate is welcome at no extra charge. Written notifications of all substitutions is required 5 working days prior to the event. Trueventus contracts carry 100% full liability upon receipt of registration. Non payment does not constitute cancellation. A 100% of cancellation fee will be charged under the terms outlined below: Due to limited event seats, Trueventus agrees to reserve the seat for the client upon issuance of invoice. Upon signing of this contract, client agrees that in case of dispute or cancellation of this contract Trueventus will not be able to mitigate its losses for any less than 50% of the total contract value. If a client does not attend the event without written notification at least 5 working days prior to the event date, he/she will deemed as no show. Trueventus does not provide refunds for cancellations. When any cancellations are notified in writing to Trueventus 5 working days prior to the event, a credit voucher will be issued for use in future Trueventus events. 4. Trueventus will at all times seek to ensure that all efforts are made to adhere to meet the advertised package, however we reserve the right to postpone, cancel or move a venue without penalty or refunds. Trueventus is not liable for any losses or damages as a result of substitution, alteration, postponement or cancellation of speakers and / or topics and / or venue and / or the event dates. If force majuere were to occur Trueventus accepts no responsibility or liability for any loss or damage caused by events beyond their control, including, but not restricted to strikes, war, civil unrest, flight delays, fire flood, or any adverse weather conditions. 5. Upon receiving this signed booking form, you the client herby consent to Trueventus to keep your details for the use of future marketing activities carried out by Trueventus and third party organisations & partners. 6. Copyright and Intellectual Property. Any redistribution or reproduction of part or all of the contents in any form in connection to this event is prohibited without prior written consent by Trueventus. 7. Client hereby agrees that he/she exclusively authorizes Trueventus charged the credit card with detials listed above for the amount provided herein; this registration form serves as a contract that is valid, binding and enforceable. He/she at any time will have no basis to claim that the payments required under this Contract are unauthorized, improper, disputed or in any way. 8. Please note that payment with credit card will be done via trueventus online credit card merchant mobile88 which will appear in the cardholder's statement. All credit card transaction will be charged in MYR. PAYMENT DETAILS Payment is due in 5 working days. By Signing and returning this form, you are accepting our terms and conditions. Please debit my: VISA MasterCard Card Number CVC/CVV2 immediately after the card s account number. This three-digit CVC/CVV2 number is printed on the signature panel on the back of the card Card Issuing Bank: Card Issuing Country: Cardholders Name Expiry Date / / Cardholders Signature Cardholder : PG.5